Product Images Otezla

This appears to be a graph showing the results of a study comparing a placebo to a medication called OTEZLA, taken twice daily. The y-axis seems to be some measure of effectiveness or improvement, while the x-axis shows the duration of the study in weeks. The number of participants taking each treatment is shown for each week. No further information is available from the given text.*

The text seems to be a medication label for Otezla (apremilast) tablets at 30 mg. It includes dosage information with two tablets indicated.*

Dosage recommendation for Otezla tablets is 330 mg to be taken twice a day. The pack contains medication for five days with a prescribed dose of 30 mg. The medicine should be stored at a temperature below 30°C. Otezla is a registered trademark belonging to Celgene Corporation. The remaining text is not readable.*

Dosage instructions for a medication with different tablet strengths are provided, with the recommended dose being a 330 mg tablet taken orally twice a day for five days. The pack contains various tablets with strengths of 10 mg, 20 mg, and 30 mg, totalling 27 tablets. The medication is a registered trademark belonging to Celgene Corporation and should be kept out of reach of children and stored at temperatures below 30°C. The text also contains instructions for taking the tablets in the morning and evening, approximately 12 hours apart.*

Otezla (apremilast) tablets come in a starter pack that is not for sale and contains four 10 mg tablets, four 20 mg tablets, and nineteen 30 mg tablets. The recommended dosage is a 30 mg tablet taken orally twice daily. The drug should be kept out of reach of children and stored below a certain temperature. Otezla is a registered trademark of Celgene Corporation, which manufactures the drug in Switzerland.*

Otezla is a medication used to treat certain types of arthritis. It is available in tablet form with a recommended dose of 30 mg taken by mouth twice daily. The pills come in different strengths of 10 mg, 20 mg, and 30 mg. The starter pack contains 21 tablets that can be used over a period of five days to gradually increase the dosage up to the prescribed amount. Otezla is a registered trademark of Celgene Corporation. It is important to keep the medication out of reach of children and store it below 207G (86℉). For more information, visit Otezla.com.*

This is a description of Otezla tablets with NDC code 59572-631-28. The recommended dosage is one 30 mg tablet taken twice daily. Otezla is a registered trademark. The full prescribing information should be consulted for dosing and administration details. The tablets should be stored below 30°C (86°F) and kept out of reach of children. The rest of the text is not readable.*

This is a description of a pharmaceutical product called Otezla. It comes in a 28-count bridge pack, containing 30mg tablets to be taken orally twice a day. The package includes twenty-eight 30mg tablets. Otezla is a registered trademark of Celgene Corporation and is manufactured in Switzerland. The label provides detailed instructions on the recommended dosage, storage conditions, and manufacturer information. Additionally, the text contains a chart with dosing information, such as when to take the tablet, the quantity of the prescribed medication, and other relevant information.*

Otezia® is a medication available in 20 mg and 30 mg tablets. It is manufactured by Celgene Corporation and used to treat various conditions such as asthma and chronic obstructive pulmonary disease. There are also 50 mg tablets available. The pills are distributed using various NDC and NOC codes, and may be purchased at pharmacies in different locations.*

This is a medication called Apremilast, available in a package of 28 tablets. The recommended dose of Apremilast is one 30 mg tablet taken orally twice daily. It's important to review the full Prescribing Information for the appropriate dosage and administration instructions. This product is not for sale and is marked as a sample. It's necessary to keep it away from children and store at a temperature below 30°C.*

This is a package insert for Otezla (apremilast) tablets. The package contains 28 tablets of 30mg each, taken orally twice daily, with instructions to take one tablet in the morning and one in the evening. Otezla is a registered trademark of Celgene Corporation and should be stored below 30°C.*

NDC 59572-631-97 is a sample of Otezla tablets (apremilast) with 28 tablets containing 30mg per tablet. This medication is taken orally, with a recommended dosage of a 30 mg tablet twice daily. The full Prescribing Information should be consulted for proper dosing and administration. It is important to keep Otezla out of reach of children and stored below 30°C (86°F).*

This is a starter pack of medication for titration over five days up to a prescribed dose of 20mg. It contains a total of 55 tablets, with four 10mg tablets, four 20mg tablets, and forty-seven 30mg tablets. One tablet seems to be missing as there is only 56 indicated on the label. The medication should be stored below 30°C (86°F) and out of reach. The medication is made by Celgenes Corporation and has Olela® as its registered trademark. The manufacturer's address is Gelgene Corporation in Summit, NJ 07901, Switzerland.*

Otezla (apremilast) tablets are used to treat psoriasis and psoriatic arthritis. This medication comes in a pack with a total of 55 tablets of three different strengths: 10mg, 20mg, and 30mg. The pack is designed to help patients titrate the medication gradually over a five-day period, up to the prescribed dose of 30mg taken twice daily. The tablets should be taken in the morning and evening, in accordance with the provided instructions. This medication is a registered trademark of Celgene Corporation and is manufactured in Switzerland. It is important to keep the tablets out of reach of children and store them below 30°C (86°F).*